During the last session, Adc Therapeutics SA (NYSE:ADCT)’s traded shares were 0.32 million, with the beta value of the company hitting 1.70. At the end of the trading day, the stock’s price was $4.34, reflecting an intraday loss of -2.25% or -$0.1. The 52-week high for the ADCT share is $6.04, that puts it down -39.17 from that peak though still a striking 91.71% gain since the share price plummeted to a 52-week low of $0.36. The company’s market capitalization is $359.40M, and the average trade volume was 719.49K shares over the past three months.
Adc Therapeutics SA (NYSE:ADCT) trade information
Adc Therapeutics SA (ADCT) registered a -2.25% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.25% in intraday trading to $4.34, hitting a weekly high. The stock’s 5-day price performance is -8.05%, and it has moved by 3.33% in 30 days. Based on these gigs, the overall price performance for the year is 121.43%.
Adc Therapeutics SA (ADCT) estimates and forecasts
Statistics show that Adc Therapeutics SA has outperformed its competitors in share price, compared to the industry in which it operates. Adc Therapeutics SA (ADCT) shares have gone up 566.67% during the last six months, with a year-to-date growth rate more than the industry average at 25.17% against 12.90. In the rating firms’ projections, revenue will increase 16.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 18.21M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 19.54M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 18.99M and 41.55M respectively. In this case, analysts expect current quarter sales to shrink by -4.10% and then drop by -53.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 84.52%. While earnings are projected to return 26.83% in 2024, the next five years will return 15.80% per annum.
ADCT Dividends
Adc Therapeutics SA is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
